Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769705 | 0.94 | P2RX7 (0.43) | P2RX7GAAMEN1LMNAKMT2A | |
| SCHEMBL4775019 | 0.93 | P2RX7 (0.41) | P2RX7GAAMEN1KMT2ACNR1 | |
| SCHEMBL4831822 | 0.90 | GAA (0.47) | P2RX7GAACNR1TRPM8MAPT | |
| SCHEMBL4767620 | 0.89 | TRPM8 (0.40) | P2RX7GAATRPM8KDM4EMAPT | |
| SCHEMBL4775080 | 0.88 | P2RX7 (0.39) | P2RX7GAAMEN1LMNAKMT2A | |
| SCHEMBL5571608 | 0.88 | P2RX7 (0.42) | P2RX7GAACNR1TRPM8 | |
| SCHEMBL4827914 | 0.88 | LMNA (0.41) | P2RX7GAAMEN1LMNAKMT2A | |
| SCHEMBL4770828 | 0.87 | P2RX7 (0.38) | P2RX7GAATRPM8 | |
| SCHEMBL4772351 | 0.87 | P2RX7 (0.43) | P2RX7GAA | |
| SCHEMBL4772423 | 0.86 | P2RX7 (0.41) | P2RX7GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | claimed |
| EP-1942888-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| WO-2007056078-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | P2RX7 4514/4885GAA 466/4885MEN1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.